Ilex Medical Ltd (TLV:ILX)
Israel
· Delayed Price · Currency is ILS · Price in ILA 6,235.00
-87.00 (-1.38%)
Apr 24, 2025, 5:24 PM IDT
Ilex Medical Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 920.37 | 930.89 | 872.54 | 1,061 | 946.45 | Upgrade
|
| Revenue Growth (YoY) | -1.13% | 6.69% | -17.76% | 12.10% | 49.29% | Upgrade
|
| Cost of Revenue | 704.06 | 699.02 | 587.44 | 681.61 | 675.43 | Upgrade
|
| Gross Profit | 216.31 | 231.87 | 285.1 | 379.38 | 271.02 | Upgrade
|
| Selling, General & Admin | 143.85 | 149.31 | 138.92 | 126.84 | 117.95 | Upgrade
|
| Research & Development | 7.62 | 9.73 | 9.4 | 8.35 | 8.42 | Upgrade
|
| Other Operating Expenses | -1.87 | -0.02 | -2.1 | -1.95 | -1.86 | Upgrade
|
| Operating Expenses | 149.6 | 159.02 | 146.23 | 133.24 | 124.51 | Upgrade
|
| Operating Income | 66.72 | 72.85 | 138.88 | 246.14 | 146.51 | Upgrade
|
| Interest Expense | -7.78 | -1.8 | -1.61 | -1.97 | -2.34 | Upgrade
|
| Interest & Investment Income | - | 0.6 | 5.77 | 1.86 | 0.85 | Upgrade
|
| Earnings From Equity Investments | -7.19 | -4.01 | -2.69 | -0.26 | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | 1.03 | -8.56 | -1.59 | 5.12 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.85 | -3.88 | -14.3 | 7.4 | 3.94 | Upgrade
|
| EBT Excluding Unusual Items | 61.6 | 64.79 | 117.5 | 251.58 | 154.07 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 4.37 | -2.72 | 3.78 | 0.09 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.24 | 21.96 | -0.01 | -0.36 | Upgrade
|
| Pretax Income | 61.6 | 69.4 | 136.74 | 255.35 | 153.8 | Upgrade
|
| Income Tax Expense | 15.89 | 18.52 | 34.62 | 57.87 | 27.83 | Upgrade
|
| Earnings From Continuing Operations | 45.7 | 50.89 | 102.12 | 197.48 | 125.97 | Upgrade
|
| Earnings From Discontinued Operations | -6.72 | - | - | - | - | Upgrade
|
| Net Income to Company | 38.98 | 50.89 | 102.12 | 197.48 | 125.97 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | -5.35 | Upgrade
|
| Net Income | 38.98 | 50.89 | 102.12 | 197.48 | 120.62 | Upgrade
|
| Net Income to Common | 38.98 | 50.89 | 102.12 | 197.48 | 120.62 | Upgrade
|
| Net Income Growth | -23.39% | -50.17% | -48.29% | 63.72% | 100.18% | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Change (YoY) | -0.18% | -0.79% | -0.02% | 5.73% | 6.33% | Upgrade
|
| EPS (Basic) | 3.49 | 4.55 | 9.05 | 17.51 | 11.30 | Upgrade
|
| EPS (Diluted) | 3.49 | 4.55 | 9.05 | 17.50 | 11.24 | Upgrade
|
| EPS Growth | -23.25% | -49.75% | -48.29% | 55.66% | 87.41% | Upgrade
|
| Free Cash Flow | 51.87 | 31.66 | 43.6 | 229.73 | 138.1 | Upgrade
|
| Free Cash Flow Per Share | 4.64 | 2.83 | 3.87 | 20.36 | 12.94 | Upgrade
|
| Dividend Per Share | - | 1.365 | 1.917 | 5.319 | 5.319 | Upgrade
|
| Dividend Growth | - | -28.80% | -63.97% | - | - | Upgrade
|
| Gross Margin | 23.50% | 24.91% | 32.67% | 35.76% | 28.63% | Upgrade
|
| Operating Margin | 7.25% | 7.83% | 15.92% | 23.20% | 15.48% | Upgrade
|
| Profit Margin | 4.23% | 5.47% | 11.70% | 18.61% | 12.75% | Upgrade
|
| Free Cash Flow Margin | 5.64% | 3.40% | 5.00% | 21.65% | 14.59% | Upgrade
|
| EBITDA | 115.81 | 106.37 | 175.2 | 296.63 | 186.4 | Upgrade
|
| EBITDA Margin | 12.58% | 11.43% | 20.08% | 27.96% | 19.70% | Upgrade
|
| D&A For EBITDA | 49.1 | 33.52 | 36.32 | 50.49 | 39.89 | Upgrade
|
| EBIT | 66.72 | 72.85 | 138.88 | 246.14 | 146.51 | Upgrade
|
| EBIT Margin | 7.25% | 7.83% | 15.92% | 23.20% | 15.48% | Upgrade
|
| Effective Tax Rate | 25.80% | 26.68% | 25.32% | 22.66% | 18.10% | Upgrade
|
| Advertising Expenses | - | 3.7 | 3.4 | 1.4 | 1.89 | Upgrade
|
Updated Nov 26, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.